Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Knowledge and skills needs for health professions about pharmacogenomics testing field.

Di Francia R, Valente D, Catapano O, Rupolo M, Tirelli U, Berretta M.

Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):781-8. Review.

PMID:
22913211
2.

Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Morley KI, Hall WD.

J Mol Med (Berl). 2004 Jan;82(1):21-30. Epub 2003 Nov 4. Review.

PMID:
14598045
3.

Pharmacogenetics: ethical issues and policy options.

Buchanan A, Califano A, Kahn J, McPherson E, Robertson J, Brody B.

Kennedy Inst Ethics J. 2002 Mar;12(1):1-15.

PMID:
12211263
4.

Pharmacogenetic testing: not as simple as it seems.

Haga SB, Burke W.

Genet Med. 2008 Jun;10(6):391-5. doi: 10.1097/GIM.0b013e31817701d4.

PMID:
18496219
5.

Ethical and social issues in pharmacogenomics testing.

Vijverberg SJ, Pieters T, Cornel MC.

Curr Pharm Des. 2010;16(2):245-52. Review.

PMID:
20205666
6.

Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Shields AE, Lerman C.

Clin Pharmacol Ther. 2008 Apr;83(4):635-9. doi: 10.1038/clpt.2008.4. Epub 2008 Mar 5. Review.

PMID:
18323859
7.

Role of genomics on the path to personalized medicine.

Tremblay J, Hamet P.

Metabolism. 2013 Jan;62 Suppl 1:S2-5. doi: 10.1016/j.metabol.2012.08.023. Epub 2012 Sep 25.

PMID:
23021037
8.

A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.

Garrison LP Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL.

Drug Metab Rev. 2008;40(2):377-401. doi: 10.1080/03602530801952500 . Review.

PMID:
18464050
9.

Ethical, social and legal implications of pharmacogenomics: a critical review.

Moldrup C.

Community Genet. 2001;4(4):204-14. Review.

PMID:
12751484
10.

Risk assessment and pharmacogenetics in molecular and genomic epidemiology.

Park SK, Choi JY.

J Prev Med Public Health. 2009 Nov;42(6):371-6. doi: 10.3961/jpmph.2009.42.6.371. Review. Erratum in: J Prev Med Public Health. 2010 Jan;43(1):96-7.

11.

[The importance of pharmacogenetics in the primary health care sector].

Møldrup C.

Ugeskr Laeger. 2002 Jun 17;164(25):3333-7. Review. Danish.

PMID:
12107946
12.

Pharmacogenomics: questions and concerns.

Mahlknecht U, Voelter-Mahlknecht S.

Curr Med Res Opin. 2005 Jul;21(7):1041-7. Review.

PMID:
16004671
13.

Emerging ethical issues in pharmacogenomics: from research to clinical practice.

Freund CL, Wilfond BS.

Am J Pharmacogenomics. 2002;2(4):273-81. Review.

PMID:
12421098
14.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
15.
16.

[Pharmacogenetics--implications for health management and health care economics].

Weihrauch TR.

Med Klin (Munich). 2002 Jul 15;97(7):420-8. German.

PMID:
12168482
17.

Pharmacogenetic challenges for the health care system.

Robertson JA, Brody B, Buchanan A, Kahn J, McPherson E.

Health Aff (Millwood). 2002 Jul-Aug;21(4):155-67.

18.

Pharmacogenetics: implementing personalized medicine.

Mini E, Nobili S.

Clin Cases Miner Bone Metab. 2009 Jan;6(1):17-24.

19.

Privacy issues in personalized medicine.

Vaszar LT, Cho MK, Raffin TA.

Pharmacogenomics. 2003 Mar;4(2):107-12.

20.

Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.

Flynn MA, McNeil DA, Maloff B, Mutasingwa D, Wu M, Ford C, Tough SC.

Obes Rev. 2006 Feb;7 Suppl 1:7-66. Review.

PMID:
16371076
Items per page

Supplemental Content

Write to the Help Desk